molecules of the month

compound 44

bioavailable bicyclic macrocycle PCSK9 inh.

%F cyno = 2.9, MW 1612, preclinical

from mRNA display screen and SBDD

Journal of Medicinal Chemistry

Merck & Co.

Chemical structure of molecule "compound 44" Merck bicyclic macrocyclic peptide PCSK9 inhibitor
1 min read

The Merck bicyclic macrocyclic peptide PCSK9 inhibitor, “compound 44,” is a highly potent (Ki = 0.00239 nM) and orally bioavailable (cyno %F = 2.9, t1/2 = 10 h) agent against a notoriously difficult target for small molecules, demonstrating target engagement comparable to approved PCSK9 antibodies. The discovery of this molecule is an interesting proof of concept for this emerging area of drug space (oral macrocyclic peptides), with hits generated by a relatively new technology (mRNA display screen) and advanced with structure-based design (potency increased by 100,000x). Several off-target issues were addressed while simultaneously lowering clearance, lipophilicity, and improving oral bioavailability. Interestingly, the clearance of the molecules was shifted over time from predominantly hepatic to renal by reducing OATP 1B1 transporter…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: